Pharmaceuticals 2010, 3(6), 1936-1948; doi:10.3390/ph3061936
Review

Unlocking the Door to Neuronal Woes in Alzheimer’s Disease: Aβ and Mitochondrial Permeability Transition Pore

1 and 1,2,3,* email
1 Department of Surgery, Physicians & Surgeons College of Columbia University, New York, NY 10032, USA 2 Department of Pathology & Cell Biology, Physicians & Surgeons College of Columbia University, New York, NY 10032, USA 3 The Taub institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University, New York, NY 10032, USA
* Author to whom correspondence should be addressed.
Received: 10 May 2010; in revised form: 10 June 2010 / Accepted: 14 June 2010 / Published: 14 June 2010
(This article belongs to the Special Issue Mitochondrial Drugs for Neurodegenerative Diseases)
PDF Full-text Download PDF Full-Text [250 KB, uploaded 15 June 2010 16:50 CEST]
Abstract: Mitochondrial dysfunction occurs early in the progression of Alzheimer’s disease. Amyloid-β peptide has deleterious effects on mitochondrial function and contributes to energy failure, respiratory chain impairment, neuronal apoptosis, and generation of reactive oxygen species in Alzheimer’s disease. The mechanisms underlying amyloid-β induced mitochondrial stress remain unclear. Emerging evidence indicates that mitochondrial permeability transition pore is important for maintenance of mitochondrial and neuronal function in aging and neurodegenerative disease. Cyclophilin D (Cyp D) plays a central role in opening mitochondrial permeability transition pores, ultimately leading to cell death. Interaction of amyloid-β with cyclophilin D triggers or enhances the formation of mitochondrial permeability transition pores, consequently exacerbating mitochondrial and neuronal dysfunction, as shown by decreased mitochondrial membrane potential, impaired mitochondrial respiration function, and increased oxidative stress and cytochrome c release. Blockade of cyclophilin D by genetic abrogation or pharmacologic inhibition protects mitochondria and neurons from amyloid-β induced toxicity, suggesting that cyclophilin D dependent mitochondrial transition pores are a therapeutic target for Alzheimer’s disease.
Keywords: amyloid beta; mitochondrial permeability transition; cyclophilin D; therapy

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Du, H.; ShiDu Yan, S. Unlocking the Door to Neuronal Woes in Alzheimer’s Disease: Aβ and Mitochondrial Permeability Transition Pore. Pharmaceuticals 2010, 3, 1936-1948.

AMA Style

Du H, ShiDu Yan S. Unlocking the Door to Neuronal Woes in Alzheimer’s Disease: Aβ and Mitochondrial Permeability Transition Pore. Pharmaceuticals. 2010; 3(6):1936-1948.

Chicago/Turabian Style

Du, Heng; ShiDu Yan, Shirley. 2010. "Unlocking the Door to Neuronal Woes in Alzheimer’s Disease: Aβ and Mitochondrial Permeability Transition Pore." Pharmaceuticals 3, no. 6: 1936-1948.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert